MOTS-c belongs to an unusual category of research peptides: it isn't produced from nuclear DNA like almost every other protein in the body. It's encoded directly within mitochondrial DNA, making it one of a small class of "mitochondrial-derived peptides" first described in 2015.
This article covers what MOTS-c is, the mechanism that distinguishes it from most metabolic peptides, what the published data actually shows, and an important distinction between MOTS-c itself and a related compound that has been tested in humans.
Prefer a quick-reference summary? See the MOTS-c Research Brief — mechanism, dosing data, and evidence tiers at a glance.
01 — What Is MOTS-c?
MOTS-c is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR, molecular formula C₁₀₁H₁₅₂N₂₈O₂₂S₂, and a molecular weight of 2,174.6 Da. Its name reflects its origin: Mitochondrial Open Reading Frame of the Twelve S-c, referring to the region of the mitochondrial 12S rRNA gene that encodes it.
This origin is what makes MOTS-c mechanistically distinct from nearly every other research peptide. The vast majority of peptides — including hormones and growth factors — are encoded by nuclear DNA and processed through the standard cellular protein pathway. MOTS-c is translated from a small open reading frame within the mitochondrial genome itself, placing it in a class of "mitochondrial-derived peptides" (MDPs) identified by researchers at USC, alongside related peptides such as humanin.
02 — Proposed Mechanisms
AMPK Activation via the Folate Cycle
MOTS-c's defining mechanism is unusual among metabolic peptides: it does not act through a conventional cell-surface receptor. Instead, published research indicates MOTS-c inhibits the folate cycle and its associated de novo purine biosynthesis pathway, which in turn activates AMPK (AMP-activated protein kinase) — a central cellular energy sensor.
This indirect, metabolism-linked activation route is mechanistically distinct from receptor-agonist peptides (such as GH secretagogues or GLP-class compounds), which bind a specific surface receptor to trigger a signalling cascade. MOTS-c's route operates through cellular energy-sensing machinery directly.
GLUT4 Upregulation and Insulin Sensitivity
Downstream of AMPK activation, published research has shown MOTS-c treatment upregulates GLUT4 expression in skeletal muscle — the primary glucose transporter responsible for insulin-stimulated glucose uptake. Because skeletal muscle accounts for the large majority of insulin-stimulated glucose disposal in the body, this mechanism is proposed as the primary route through which MOTS-c influences insulin sensitivity in preclinical models.
Mitochondrial Fusion Dependence
More recent research has found that MOTS-c's ability to promote GLUT4 translocation depends on mitochondrial fusion — the process by which mitochondria join to form networks. This adds a structural dimension to the mechanism beyond the AMPK/folate cycle pathway alone, and is an active area of ongoing investigation.
03 — What the Published Studies Show
The Foundational 2015 Study
The landmark paper establishing MOTS-c's metabolic role was published in Cell Metabolism in 2015. In mouse models, MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance, and prevented diet-induced obesity. In aged mice, MOTS-c treatment improved insulin sensitivity toward levels seen in young animals.
Preclinical evidence for metabolic and muscle-related effects has since been replicated and extended across multiple independent research groups. Controlled human trial data for MOTS-c itself, however, remains absent at the time of writing.
CB4211 — An Analog, Not MOTS-c Itself
This distinction matters and is frequently blurred in casual discussion of MOTS-c: the only human clinical trial data associated with this peptide class comes from CB4211, a modified analog of MOTS-c developed by CohBar for nonalcoholic steatohepatitis (NASH) and obesity — not native MOTS-c.
CB4211 completed a Phase 1a trial (65 healthy volunteers, single and multiple ascending dose) and a Phase 1b trial (20 obese subjects with NAFLD, 25mg/day subcutaneous for 4 weeks). The compound was reported safe and well tolerated, with biomarker improvements including a 21% reduction in serum ALT, 28% reduction in serum AST, and 6% reduction in fasting glucose. The programme did not advance to Phase 2 — not due to a negative efficacy or safety finding, but because of funding and operational challenges at the company.
This CB4211 data should not be read as human evidence for MOTS-c itself. It is evidence for a related but distinct engineered analog.
A New Trial Testing MOTS-c Directly
A clinical trial specifically evaluating native MOTS-c for improving insulin sensitivity in adults with prediabetes and overweight/obesity is now registered (ClinicalTrials.gov NCT07505745). This is the first trial to test MOTS-c itself in humans, rather than an analog. No results have been published at the time of writing.
04 — What Is Not Yet Established
No published human trial data exists for native MOTS-c — the CB4211 analog data does not transfer directly, and the newly registered direct trial has not yet reported results
The precise mechanistic link between AMPK activation and downstream metabolic effects is still being characterised — the mitochondrial fusion dependence finding is recent and not yet fully integrated into the broader mechanistic picture
Optimal research parameters (concentration, administration route, frequency) for laboratory applications are not established in standardised published protocols
Long-term effects beyond the study windows in the available preclinical literature have not been characterised
05 — Research Formats
MOTS-c is available as a lyophilised powder for research applications. It requires reconstitution with bacteriostatic water before use in any research protocol. Full reconstitution guide →
Unreconstituted vials should be stored refrigerated. Reconstituted solutions should be kept refrigerated and used within 28–30 days.
